OTTAWA, ONTARIO--(Marketwire - May 11, 2010) - PharmaGap Inc. (TSX VENTURE:GAP) (OTCBB:PHRGF) ("PharmaGap" or "the Company") is pleased to announce that it has now received results of testing of its lead cancer drug GAP-107B8, at the National Cancer Center ("NCI") in Bethesda, MD, and is currently in the final stages of analyzing the data generated. Results will be announced in a few days.

Late last year the NCI tested the Company's lead cancer drug in the NCI's 60 cell human cancer tumour panel at a single dose concentration of 10 micromolars, and in a 5 dose range of up to 100 micromolars. The results of these tests were previously reported. After discussion with the Company, the NCI undertook a further testing program at a much narrower dose range of 5 micromolar to 80 micromolar concentration, consistent with previous in vitro testing of GAP-107B8 and consistent with established effective dose ranges for peptide drug compounds.

This test program began in January. Initial test results were made available to the Company in the first quarter. At the NCI's initiative, this test was run a second time to confirm the earlier findings, and the Company has now received the data from these tests. These latest test results will be announced within a few days following completion of analysis.

The Company has also been advised by SC Stormont Inc. ("Stormont") that Stormont has retained Mr. Martin Tremblay to provide investor relations services to PharmaGap as part of the Strategic Leadership Agreement between PharmaGap and Stormont.